PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Diagnostic Roles of Immunohistochemical Markers, CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ: A Meta-Analysis and Diagnostic Test Accuracy Review
Yoo, D.-S.; Min, K.W.; Pyo, J.S.; Shin, H.B.; Kim, N.Y. Diagnostic Roles of Immunohistochemical Markers, CK20, CD44, AMACR, and P53 in Urothelial Carcinoma in Situ: A Meta-Analysis and Diagnostic Test Accuracy Review. European Urology Open Science 2023, 57, S285–S286, doi:10.1016/s2666-1683(23)01497-0.
Yoo, D.-S.; Min, K.W.; Pyo, J.S.; Shin, H.B.; Kim, N.Y. Diagnostic Roles of Immunohistochemical Markers, CK20, CD44, AMACR, and P53 in Urothelial Carcinoma in Situ: A Meta-Analysis and Diagnostic Test Accuracy Review. European Urology Open Science 2023, 57, S285–S286, doi:10.1016/s2666-1683(23)01497-0.
Yoo, D.-S.; Min, K.W.; Pyo, J.S.; Shin, H.B.; Kim, N.Y. Diagnostic Roles of Immunohistochemical Markers, CK20, CD44, AMACR, and P53 in Urothelial Carcinoma in Situ: A Meta-Analysis and Diagnostic Test Accuracy Review. European Urology Open Science 2023, 57, S285–S286, doi:10.1016/s2666-1683(23)01497-0.
Yoo, D.-S.; Min, K.W.; Pyo, J.S.; Shin, H.B.; Kim, N.Y. Diagnostic Roles of Immunohistochemical Markers, CK20, CD44, AMACR, and P53 in Urothelial Carcinoma in Situ: A Meta-Analysis and Diagnostic Test Accuracy Review. European Urology Open Science 2023, 57, S285–S286, doi:10.1016/s2666-1683(23)01497-0.
Abstract
This study aimed to evaluate the diagnostic roles of various immunohistochemical markers in urothelial carcinoma in situ (uCIS) through a meta-analysis and review of diagnostic test accuracy. Immunohistochemical markers CK20, CD44, AMACR, and p53 were evaluated in the present study. We analyzed the expression rates of immunohistochemical markers and compared their diagnostic accuracies. The estimated expression rates were 0.803 (95% confidence interval [CI]: 0.726–0.862), 0.142 (95% CI: 0.033–0.449), 0.824 (95% CI: 0.720–0.895), and 0.600 (95% CI: 0.510–0.683) for CK20, CD44, AMACR, and p53, respectively. In the comparison between uCIS and reactive/normal urothelium, the expression of CK20, AMACR, and p53 in uCIS was significantly higher than in reactive/normal urothelium. CD44 showed significantly lower expression in uCIS than in the reactive/normal urothelium. Among the markers, AMACR had the highest sensitivity, specificity, and diagnostic odds ratio. The AUC on SROC was the highest for CK20. In conclusion, immunohistochemical markers, such as CK20, CD44, AMACR, and p53, can be useful in differentiating uCIS from reactive/normal urothelium.
Keywords
urothelial carcinoma in situ; immunohistochemistry; meta-analysis; diagnostic test accuracy review
Subject
Medicine and Pharmacology, Pathology and Pathobiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
